{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:04:14Z","timestamp":1784966654994,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human rabies remains a globally significant public health problem. Replacement of polyclonal anti-rabies immunoglobulin (RIG), a passive component of rabies post-exposure prophylaxis (PEP), with a monoclonal antibody (MAb), would eliminate the cost and availability constraints associated with RIG. Our team has developed and licensed a human monoclonal antibody RAB1 (Rabishield<jats:sup>\u00a9<\/jats:sup>), as the replacement for RIG where canine rabies is enzootic. However, for the highly diverse rabies viruses of North America, a cocktail containing two or more MAbs targeting different antigenic sites of the rabies glycoprotein should be included to ensure neutralization of all variants of the virus. In this study, two MAb cocktails, R172 (RAB1-RAB2) and R173 (RAB1-CR57), were identified and evaluated against a broad range of rabies variants from North America. R173 was found to be the most potent cocktail, as it neutralized all the tested North American RABV isolates and demonstrated broad coverage of isolates from both terrestrial and bat species. R173 could be a promising candidate as an alternative or replacement for RIG PEP in North America.<\/jats:p>","DOI":"10.1038\/s41598-022-13527-0","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T19:14:24Z","timestamp":1654629264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis"],"prefix":"10.1038","volume":"12","author":[{"given":"Monir","family":"Ejemel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix R.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint N.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock E.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Kling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Gallardo-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Buzby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sullivan-Bolyai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"13527_CR1","unstructured":"American Academy of Pediatrics CoIDPLKBCJKDWLSSAAoPCoID. Red book : 2012 report of the Committee on Infectious Diseases (2012)."},{"key":"13527_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003709","volume":"9","author":"K Hampson","year":"2015","unstructured":"Hampson, K. et al. Estimating the global burden of endemic canine rabies. PLoS Negl. Trop. Dis. 9, e0003709 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"13527_CR3","first-page":"360","volume":"83","author":"DL Knobel","year":"2005","unstructured":"Knobel, D. L. et al. Re-evaluating the burden of rabies in Africa and Asia. Bull. World Health Organ. 83, 360\u2013368 (2005).","journal-title":"Bull. World Health Organ."},{"key":"13527_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2460\/javma.256.2.195","volume":"256","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Rabies surveillance in the United States during 2018. J. Am. Vet. Med. Assoc. 256, 195\u2013208 (2020).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"13527_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s11908-012-0268-2","volume":"14","author":"HM Feder Jr","year":"2012","unstructured":"Feder, H. M. Jr., Petersen, B. W., Robertson, K. L. & Rupprecht, C. E. Rabies: still a uniformly fatal disease? Historical occurrence, epidemiological trends, and paradigm shifts. Curr. Infect. Dis. Rep. 14, 408\u2013422 (2012).","journal-title":"Curr. Infect. Dis. Rep."},{"key":"13527_CR6","doi-asserted-by":"publisher","first-page":"7156","DOI":"10.1016\/j.vaccine.2009.09.028","volume":"27","author":"KA Christian","year":"2009","unstructured":"Christian, K. A., Blanton, J. D., Auslander, M. & Rupprecht, C. E. Epidemiology of rabies post-exposure prophylaxis\u2013United States of America, 2006\u20132008. Vaccine 27, 7156\u20137161 (2009).","journal-title":"Vaccine"},{"key":"13527_CR7","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.1097\/PHH.0000000000000125","volume":"21","author":"NM Vora","year":"2015","unstructured":"Vora, N. M., Clippard, J. R., Stobierski, M. G., Signs, K. & Blanton, J. D. Animal bite and rabies postexposure prophylaxis reporting\u2013United States, 2013. J. Public Health Manag. Pract. 21, E24\u2013E27 (2015).","journal-title":"J. Public Health Manag. Pract."},{"key":"13527_CR8","unstructured":"WHO. WHO consultation on a monoclonal antibody cocktail for rabies post exposure treatment (2002)."},{"key":"13527_CR9","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","volume":"25","author":"SE Sloan","year":"2007","unstructured":"Sloan, S. E. et al. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 25, 2800\u20132810 (2007).","journal-title":"Vaccine"},{"key":"13527_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.antiviral.2011.06.002","volume":"91","author":"Y Wang","year":"2011","unstructured":"Wang, Y. et al. G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates. Antiviral. Res. 91, 187\u2013194 (2011).","journal-title":"Antiviral. Res."},{"key":"13527_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2460\/javma.256.1.77","volume":"256","author":"EG Pieracci","year":"2020","unstructured":"Pieracci, E. G. et al. Evaluation of species identification and rabies virus characterization among bat rabies cases in the United States. J. Am. Vet. Med. Assoc. 256, 77\u201384 (2020).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"13527_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/tropicalmed2010001","volume":"2","author":"R Franka","year":"2017","unstructured":"Franka, R. et al. In vivo efficacy of a cocktail of human monoclonal antibodies (CL184) against diverse north American bat rabies virus variants. Trop. Med. Infect. Dis. 2, 1 (2017).","journal-title":"Trop. Med. Infect. Dis."},{"key":"13527_CR13","unstructured":"Anonymous. WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser: 1\u2013139, back cover (2013)."},{"key":"13527_CR14","unstructured":"FDA. Rabies: Developing Monoclonal Antibody Cocktails for the Passive Immunization Component of Post-Exposure Prophylaxis, Guidance for Industry (2021)."},{"key":"13527_CR15","doi-asserted-by":"publisher","first-page":"10537","DOI":"10.1128\/JVI.77.19.10537-10547.2003","volume":"77","author":"C Pr\u00e9haud","year":"2003","unstructured":"Pr\u00e9haud, C., Lay, S., Dietzschold, B. & Lafon, M. Glycoprotein of nonpathogenic rabies viruses is a key determinant of human cell apoptosis. J. Virol. 77, 10537\u201310547 (2003).","journal-title":"J. Virol."},{"key":"13527_CR16","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1128\/jvi.69.11.6705-6711.1995","volume":"69","author":"J He","year":"1995","unstructured":"He, J. et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69, 6705\u20136711 (1995).","journal-title":"J. Virol."},{"key":"13527_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1006\/viro.1995.1016","volume":"206","author":"RI Connor","year":"1995","unstructured":"Connor, R. I., Chen, B. K., Choe, S. & Landau, N. R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206, 935\u2013944 (1995).","journal-title":"Virology"},{"key":"13527_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/B978-0-12-801919-1.00017-8","volume-title":"Current laboratory techniques in rabies diagnosis, research and prevention","author":"ML Yager","year":"2015","unstructured":"Yager, M. L. & Moore, S. M. The Rapid Fluorescent Focus Inhibition Test. In Current laboratory techniques in rabies diagnosis, research and prevention Vol. 2 (eds Rupprecht, C. & Nagarajan, T.) 199\u2013214 (Academic Press, 2015)."},{"key":"13527_CR19","first-page":"88","volume-title":"Laboratory techniques in rabies","author":"DJ Dean","year":"1996","unstructured":"Dean, D. J., Abelseth, M. K. & Atanasiu, P. The fluorescent antibody test. In Laboratory techniques in rabies 4th edn (eds Meslin, F. X. et al.) 88\u201395 (World Health Organization, 1996).","edition":"4"},{"key":"13527_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005258","volume":"11","author":"A Wadhwa","year":"2017","unstructured":"Wadhwa, A. et al. A pan-lyssavirus taqman real-time RT-PCR assay for the detection of highly variable rabies virus and other lyssaviruses. PLoS Negl. Trop. Dis. 11, e0005258 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"13527_CR21","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1128\/jvi.64.6.3087-3090.1990","volume":"64","author":"B Dietzschold","year":"1990","unstructured":"Dietzschold, B. et al. Biological characterization of human monoclonal antibodies to rabies virus. J. Virol. 64, 3087\u20133090 (1990).","journal-title":"J. Virol."},{"key":"13527_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v8110279","volume":"8","author":"S Zhu","year":"2016","unstructured":"Zhu, S. & Guo, C. Rabies control and treatment: from prophylaxis to strategies with curative potential. Viruses 8, 1 (2016).","journal-title":"Viruses"},{"key":"13527_CR23","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.tim.2018.07.001","volume":"26","author":"K Brunker","year":"2018","unstructured":"Brunker, K. & Mollentze, N. Rabies virus. Trends Microbiol. 26, 886\u2013887 (2018).","journal-title":"Trends Microbiol."},{"issue":"Suppl 1","key":"13527_CR24","doi-asserted-by":"publisher","first-page":"A88","DOI":"10.1016\/j.vaccine.2018.10.103","volume":"37","author":"A Tarantola","year":"2019","unstructured":"Tarantola, A., Tejiokem, M. C. & Briggs, D. J. Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines. Vaccine 37(Suppl 1), A88\u2013A93 (2019).","journal-title":"Vaccine"},{"key":"13527_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/archinte.1991.00400040147044","volume":"151","author":"FL Reid-Sanden","year":"1991","unstructured":"Reid-Sanden, F. L., Fishbein, D. B., Stevens, C. A. & Briggs, D. J. Administration of rabies vaccine in the gluteal area: A continuing problem. Arch. Intern. Med. 151, 821 (1991).","journal-title":"Arch. Intern. Med."},{"key":"13527_CR26","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2146\/ajhp170066","volume":"74","author":"VC Ziesenitz","year":"2017","unstructured":"Ziesenitz, V. C., Mazer-Amirshahi, M., Zocchi, M. S., Fox, E. R. & May, L. S. U.S. vaccine and immune globulin product shortages, 2001\u201315. Am. J. Health Syst. Pharm. 74, 1879\u20131886 (2017).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"13527_CR27","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","volume":"9","author":"T Abreu-Mota","year":"2018","unstructured":"Abreu-Mota, T. et al. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. Nat. Commun. 9, 4223 (2018).","journal-title":"Nat. Commun."},{"key":"13527_CR28","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/ijph.IJPH_365_19","volume":"63","author":"AN Dh","year":"2019","unstructured":"Dh, A. N. & Haradanhalli, R. S. Assessment of procurement, distribution, availability, and utilization of rabies biologicals for postexposure prophylaxis in seven states of India. Indian J. Public Health 63, S31\u2013S36 (2019).","journal-title":"Indian J. Public Health"},{"issue":"Suppl 1","key":"13527_CR29","doi-asserted-by":"publisher","first-page":"A128","DOI":"10.1016\/j.vaccine.2019.07.087","volume":"37","author":"OK Bharti","year":"2019","unstructured":"Bharti, O. K., Thakur, B. & Rao, R. Wound-only injection of rabies immunoglobulin (RIG) saves lives and costs less than a dollar per patient by \u201cpooling strategy\u201d. Vaccine 37(Suppl 1), A128\u2013A131 (2019).","journal-title":"Vaccine"},{"key":"13527_CR30","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1080\/21645515.2020.1854000","volume":"17","author":"N Hobart-Porter","year":"2021","unstructured":"Hobart-Porter, N. et al. Safety and efficacy of rabies immunoglobulin in pediatric patients with suspected exposure. Hum. Vaccin. Immunother 17, 2090\u20132096 (2021).","journal-title":"Hum. Vaccin. Immunother"},{"key":"13527_CR31","first-page":"67","volume":"317","author":"T Nagarajan","year":"2008","unstructured":"Nagarajan, T. et al. Human monoclonal antibody and vaccine approaches to prevent human rabies. Curr. Top. Microbiol. Immunol. 317, 67\u2013101 (2008).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"13527_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222198","volume":"14","author":"GS Gill","year":"2019","unstructured":"Gill, G. S. et al. Estimation of the incidence of animal rabies in Punjab India. PLoS ONE 14, e0222198 (2019).","journal-title":"PLoS ONE"},{"key":"13527_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v12111255","volume":"12","author":"CM Gigante","year":"2020","unstructured":"Gigante, C. M. et al. Portable rabies virus sequencing in canine rabies endemic countries using the Oxford Nanopore MinION. Viruses 12, 1 (2020).","journal-title":"Viruses"},{"key":"13527_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1073\/pnas.80.1.70","volume":"80","author":"B Dietzschold","year":"1983","unstructured":"Dietzschold, B. et al. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc. Natl. Acad. Sci. USA 80, 70\u201374 (1983).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"13527_CR35","first-page":"3","volume":"17","author":"A Diallo","year":"1986","unstructured":"Diallo, A. Avirulent mutants of the rabies virus: change in site III of the glycoprotein. Ann. Rech. Vet. 17, 3\u20136 (1986).","journal-title":"Ann. Rech. Vet."},{"key":"13527_CR36","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1128\/JVI.79.8.4672-4678.2005","volume":"79","author":"WE Marissen","year":"2005","unstructured":"Marissen, W. E. et al. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: Fine mapping and escape mutant analysis. J. Virol. 79, 4672\u20134678 (2005).","journal-title":"J. Virol."},{"key":"13527_CR37","doi-asserted-by":"publisher","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","volume":"79","author":"AB Bakker","year":"2005","unstructured":"Bakker, A. B. et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol. 79, 9062\u20139068 (2005).","journal-title":"J. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13527-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13527-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13527-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T20:02:45Z","timestamp":1700683365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13527-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13527"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13527-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9403"}}